Online first
Research paper
Published online: 2022-08-01

open access

Page views 698
Article views/downloads 454
Get Citation

Connect on Social Media

Connect on Social Media

LncRNA-loc391533 is involved in the progression of preeclampsia through VEGF

Jun Xiong1, Xuan Jin2, Kangxiang Xu3, Bingqi Wu3, Yuqi Xu3, Dong Ruan3, Xiaoju He1

Abstract

Objectives: Preeclampsia (PE) is a leading cause of maternal death worldwide, which is one of the most major pregnancy complications. The effects of vascular endothelial growth factor (VEGF) and lncRNA-loc391533 on PE were evaluated in the present study.

Material and methods: Expression of VEGF in pregnant women with PE was determined using immunohistochemical and enzyme linked immunosorbent assay (ELISA). The effects of lncRNA-loc391533 knockdown and overexpression on VEGF expression was detected using quantitative polymerase chain reaction (qPCR) and western blotting. Loss/gain-of-function assays were performed to evaluate the role of lncRNA-loc391533 on proliferation, cell cycle and migration of trophoblasts HTR-8/SVneo cells.

Results: We found that VEGF and its receptor VEGFR1/2 were low expressed in PE. Knockdown of lncRNA-loc391533 enhanced VEGF expression, while overexpression of lncRNA-loc391533 downregulated VEGF. Moreover, lncRNA-loc391533 was required for proliferation and migration of HTR-8/SVneo cells.

Conclusions: In conclusion, our findings emphasized that lncRNA-loc391533 exhibited a critical role in progression of PE through VEGF, which might as a novel therapeutic target for PE treatment.

Article available in PDF format

View PDF Download PDF file

References

  1. American College of Obstetricians and Bulletins-Obstetrics Gynecologists Committee on Practice 2020. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020; 135(6): e237–e260.
  2. Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014; 4(2): 97–104.
  3. Lisonkova S, Sabr Y, Mayer M, et al. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol. 2014; 124(4): 771–781.
  4. Tomimatsu T, Mimura K, Matsuzaki S. Preeclampsia: maternal systemic vascular disorder caused by generalized endothelial dysfunction due to placental antiangiogenic factors. Int J Mol Sci. 2019; 20(17): 4246.
  5. Cox AG, Marshall SA, Palmer KR, et al. Current and emerging pharmacotherapy for emergency management of preeclampsia. Expert Opin Pharmacother. 2019; 20(6): 701–712.
  6. Birney E, Stamatoyannopoulos JA, Dutta A, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007; 447(7146): 799–816.
  7. Kapranov P, Cheng J, Dike S, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science. 2007; 316(5830): 1484–1488.
  8. Rinn JL, Kertesz M, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007; 129(7): 1311–1323.
  9. Chen L, Dzakah EE, Shan G. Targetable long non-coding RNAs in cancer treatments. Cancer Lett. 2018; 418: 119–124.
  10. Luo Q, Chen Y. Long noncoding RNAs and Alzheimer's disease. Clin Interv Aging. 2016; 11: 867–872.
  11. Chanda K, Das S, Chakraborty J, et al. Altered levels of long NcRNAs meg3 and neat1 in cell and animal models of Huntington's disease. RNA Biol. 2018; 15(10): 1348–1363.
  12. Huang Y. The novel regulatory role of lncRNA-miRNA-mRNA axis in cardiovascular diseases. J Cell Mol Med. 2018; 22(12): 5768–5775.
  13. Sui W, Lin H, Peng W, et al. Molecular dysfunctions in acute rejection after renal transplantation revealed by integrated analysis of transcription factor, microRNA and long noncoding RNA. Genomics. 2013; 102(4): 310–322.
  14. Song X, Luo X, Gao Q, et al. Dysregulation of lncRNAs in placenta and pathogenesis of preeclampsia. Curr Drug Targets. 2017; 18(10): 1165–1170.
  15. Wu JL, Wang YG, Gao GM. Overexpression of lncRNA TCL6 promotes preeclampsia progression by regulating PTEN. Eur Rev Med Pharmacol Sci. 2019; 23(10): 4066–4072.
  16. Haonon O, Rucksaken R, Pinlaor P, et al. Upregulation of 14-3-3 eta in chronic liver fluke infection is a potential diagnostic marker of cholangiocarcinoma. Proteomics Clin Appl. 2016; 10(3): 248–256.
  17. Liu Z, Li J, Chen J, et al. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression . BMC Cancer. 2018; 18(1): 200.
  18. Konstantinou GN. Enzyme-Linked Immunosorbent Assay (ELISA). Methods Mol Biol. 2017; 1592: 79–94.
  19. Trapiella-Alfonso L, Alexandre L, Fraichard C, et al. VEGF (vascular endothelial growth factor) functionalized magnetic beads in a microfluidic device to improve the angiogenic balance in preeclampsia . Hypertension. 2019; 74(1): 145–153.
  20. Role of dyslipidemia in preeclampsia: A review of lipidomic analysis of blood, placenta, syncytiotrophoblast microvesicles and umbilical cord artery from women with preeclampsia . Prostaglandins Other Lipid Mediat. 2018; 139: 19–23.
  21. Rana S, Lemoine E, Granger JP, et al. Preeclampsia. Circ Res. 2019; 124(7): 1094–1112.
  22. ACOG Committee Opinion No. 743: Low-dose aspirin use during pregnancy. Obstet Gynecol. 2018; 132(1): e44–e52.
  23. Thadhani R, Hagmann H, Schaarschmidt W, et al. removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia . J Am Soc Nephrol. 2016; 27(3): 903–913.
  24. Leanos-Miranda A, Campos-Galicia I, Berumen-Lechuga MG, et al. circulating angiogenic factors and the risk of preeclampsia in systemic lupus erythematosus pregnancies . J Rheumatol. 2015; 42(7): 1141–1149.
  25. Xiao Z, Li S, Yu Y, et al. VEGF-A regulates sFlt-1 production in trophoblasts through both Flt-1 and KDR receptors. Mol Cell Biochem. 2018; 449(1–2): 1–8.
  26. Alahakoon TI, Medbury H, Williams H, et al. Maternal Flt-1 and endoglin expression by circulating monocyte subtype and polarization in preeclampsia and fetal growth restriction. Eur J Obstet Gynecol Reprod Biol X. 2019; 3: 100024.
  27. Hodel M, Blank PR, Marty P. sFlt-1/PlGF ratio as a predictive marker in women with suspected preeclampsia: an economic evaluation from a Swiss perspective. Dis Markers. 2019; 2019: 4096847.
  28. Zou Y, Li Q, Xu Y, et al. Promotion of trophoblast invasion by lncRNA MVIH through inducing Jun-B . J Cell Mol Med. 2018; 22(2): 1214–1223.
  29. Liu X, Chen H, Kong W, et al. Down-regulated long non-coding RNA-ATB in preeclampsia and its effect on suppressing migration, proliferation, and tube formation of trophoblast cells . Placenta. 2017; 49: 80–87.
  30. Li Q, Zhang J, Su DM. lncRNA TUG1 modulates proliferation, apoptosis, invasion, and angiogenesis via targeting miR-29b in trophoblast cells . Hum Genomics. 2019; 13(1): 50.